The National Institute on Drug Abuse<\/a> (NIDA) Risk Behavior Assessment<\/strong> (RBA) is an interviewer-administered, semi-structured epidemiological and behavioral assessment tool designed to systematically document high-risk behaviors associated with the transmission of the Human Immunodeficiency Virus<\/a> (HIV), Hepatitis B Virus<\/a> (HBV), Hepatitis C Virus<\/a> (HCV), and other sexually transmitted infections<\/a> (STIs). Originally developed by NIDA\u2019s Community Research Branch in conjunction with principal investigators of the NIDA Cooperative Agreement for HIV\/AIDS Community-Based Outreach\/Intervention Research program, the RBA evaluates high-risk populations not in drug treatment, particularly injection drug users (IDUs) and crack cocaine users. The instrument comprises 12 distinct sections (Sections P and A through K) capturing sociodemographic characteristics, drug use patterns, injection practices, 48-hour drug recall, treatment history, detailed sexual practices categorized by partner gender, commercial sex work\/trading, medical diagnoses, legal\/incarceration history, socioeconomic status, and interviewer validity impressions. Administration takes approximately 18 to 60 minutes using absolute frequencies, numerical continuous counts, and categorical skip patterns. Psychometric evaluations using 48-hour test-retest paradigms demonstrate robust reliability across major behavioral domains, with test-retest coefficients ranging from moderate to exceptional (.50 to .92 for sexual risk items; .70 to .95 for drug consumption frequencies). Biological criterion-related validity has been confirmed via urinalysis for recent substance use and serological assays for viral and bacterial pathogens including HIV, hepatitis, and syphilis. As an open-access public domain instrument, the RBA and its longitudinal companion, the Risk Behavior Follow-up Assessment (RBFA), serve as foundational measurement standards in public health surveillance, harm reduction evaluation, and behavioral epidemiology.<\/p>\n Risk Behavior Assessment, RBA, HIV risk behavior, injection drug use, sexual risk behavior, NIDA Cooperative Agreement, psychometrics, test-retest reliability, criterion validity, substance use assessment<\/p>\n The Risk Behavior Assessment was developed through a multi-site collaborative initiative spearheaded by the Community Research Branch of the National Institute on Drug Abuse (NIDA)<\/strong> in conjunction with principal investigators from the Cooperative Agreement for HIV\/AIDS Community-Based Outreach\/Intervention Research Program<\/em>. Key academic contributors and principal investigators responsible for the psychometric refinement, standardization, and extensive field validation include:<\/p>\n The primary purpose of the Risk Behavior Assessment (RBA) is to provide an objective, standardized, and clinically rigorous assessment of behaviors that expose individuals to infectious blood-borne and sexually transmitted pathogens. Conceived during the height of the HIV\/AIDS epidemic among out-of-treatment drug-using populations, the instrument addresses the pressing need for a cross-site, standardized measurement battery capable of quantifying behavioral frequencies over specific recall windows (predominantly 30 days and 48 hours).<\/p>\n In clinical and preventive intervention settings, the RBA serves several vital functions:<\/p>\n The RBA does not operationalize a singular latent personality trait or psychological syndrome; rather, it assesses multidimensional behavioral constructs operationalized under the broader framework of Health-Risk Behavior<\/strong> and Infectious Disease Risk Topography<\/strong>. Each section targets discrete, measurable operational behaviors that directly govern pathogen exposure pathways:<\/p>\n This construct captures the absolute frequency, duration, and specific routes of administration (oral, nasal insufflation, inhalation\/smoking, subcutaneous injection, and intravenous injection) across distinct psychoactive drug classes. The measured classes encompass alcohol, cannabis, crack cocaine, powder cocaine, heroin, speedballs (cocaine and heroin combined), nonprescription methadone, other illicit or diverted prescription opiates, and amphetamines. Section D measures acute substance use over the past 48 hours, establishing a baseline for immediate recall that can be directly verified against physiological urine toxicology.<\/p>\n Administered exclusively to respondents who have injected drugs within the preceding 30 days, this dimension evaluates behavioral vectors that facilitate the direct and indirect exchange of infected blood. Specific constructs include:<\/p>\n Recognizing the profound heterogeneity of human sexual behavior, Section F stratifies respondents into six distinct sexual orientation and partner-gender behavioral subsets: men who have sex exclusively with men (MSM), men who have sex with women (MSW), men who have sex with both men and women (MSMW), women who have sex exclusively with women (WSW), women who have sex with men (WSM), and women who have sex with both men and women (WSMW). The measured constructs focus on precise event counts over the last 30 days:<\/p>\n This dimension operationalizes the economic commodification of sexual practices, capturing frequencies of providing or receiving sexual acts in exchange for monetary compensation, illicit drugs, shelter, food, or safety. It measures vulnerability to coercive sexual dynamics, diminished condom negotiation leverage, and rapid partner turnover.<\/p>\n These auxiliary behavioral and contextual dimensions capture broader social determinants of health:<\/p>\n The architecture of the Risk Behavior Assessment is underpinned by integrated paradigms from behavioral epidemiology<\/a>, harm reduction<\/a>, and Social Cognitive Theory<\/a> (Bandura, 1986). Rather than viewing risky behavior as an irrational manifestation of psychopathology, the RBA conceptualizes behavior as the direct interface between individual agency, drug-related cognitive alterations, physiological dependence, and structural socioeconomic constraints.<\/p>\n Several theoretical tenets direct the instrument’s operational structure:<\/p>\n The construct, criterion-related, convergent, and discriminant validities of the Risk Behavior Assessment have been rigorously analyzed through dozens of multi-site field studies across diverse geographical cohorts within the United States.<\/p>\n A persistent methodological challenge in behavioral substance research involves the veracity of self-reported drug administration. To validate self-report, researchers within the NIDA Cooperative Agreement instituted systematic urinalysis protocols that compared self-reported recent drug consumption (Section D: past 48 hours) against biological drug metabolite assays (Dowling-Guyer et al., 1994; Weatherby et al., 1994). Findings revealed high rates of concordance:<\/p>\n The validity of Section H (Health-Related Conditions) has been corroborated using clinical diagnostic records and serological markers:<\/p>\n The RBA demonstrates robust construct and predictive validity by consistently mirroring known epidemiological gradients. Longitudinal analyses show that higher baseline injecting risk scores (e.g., frequent needle sharing, unsterile water source utilization) prospectively predict incident seroconversion for HCV and HBV. Similarly, frequency counts of unprotected insertive\/receptive anal sex recorded in Section F reliably predict acquisition of bacterial STIs and HIV across multi-year cohort observations (Needle et al., 1995).<\/p>\n The reliability of the RBA has been extensively evaluated across multiple centers using rigorous 48-hour test-retest paradigms<\/strong>. Because behavioral frequencies are subject to dynamic real-world shifts over extended timeframes, a 48-hour test-retest window allows evaluation of measurement stability before true behavioral rates undergo meaningful secular change.<\/p>\n Dowling-Guyer, Johnson, Fisher, and Needle (1994) conducted definitive psychometric evaluations of the revised RBA sexual risk variables across diverse cohorts. The 48-hour test-retest reliability coefficients exhibited domain-dependent variation:<\/p>\n Initial studies by Needle et al. (1995) and Weatherby et al. (1994) revealed that while general substance use frequencies were exceptionally stable (coefficients consistently between .75 and .95), early iterations of syringe-sharing items showed variability due to ambiguous wording regarding direct versus indirect sharing. The revised RBA corrected these ambiguities by defining distinct paraphernalia elements (syringes, cookers, cotton, rinse water). Re-evaluation confirmed that 48-hour test-retest reliability for injecting frequency, frequency of using clean needles, and specific cooker sharing stabilized with coefficients exceeding .70 to .85 (Dowling-Guyer et al., 1994).<\/p>\n Subsequent psychometric investigations have established the temporal stability of the RBA’s supplemental modules:<\/p>\n Unlike psychometric scales developed within classical test theory to measure latent psychological constructs (such as neuroticism, depression, or general intelligence), the RBA was constructed as an objective behavioral survey and epidemiological inventory<\/strong>. Because its indicators reflect discrete behavioral counts, the global instrument does not adhere to a single continuous unidimensional factor model. However, extensive exploratory factor analyses (EFA), confirmatory factor analyses (CFA), and structural equation models (SEM) have been performed on individual sections and integrated risk subsets.<\/p>\n Factor analytic treatments of Section B (Drug Use) and Section C (Injection Practices) consistently yield distinct, multi-factorial solutions rather than a generalized “addiction severity” factor. EFAs utilizing principal axis factoring and promax (oblique) rotation typically resolve into three to four robust factors:<\/p>\n Factor analyses conducted on Section F (Sexual Risk Behavior) reliably confirm a bifurcated structural pattern dividing risk into two distinct behavioral domains:<\/p>\n Model fit indices for confirmatory factor models examining these risk subdomains in large community cohorts demonstrate acceptable parameters (e.g., Comparative Fit Index [CFI] > .93, Tucker-Lewis Index [TLI] > .91, and Root Mean Square Error of Approximation [RMSEA] < .05), validating the structural division between parenteral risk and sexual transmission risk<\/span>.<\/p>\n The Risk Behavior Assessment (RBA) was originally formulated in 1991 and revised substantially through 1993\u20131994 by the Community Research Branch of the National Institute on Drug Abuse (NIDA), an operating agency of the National Institutes of Health<\/a> (NIH), United States Department of Health and Human Services.<\/p>\n Copyright and Public Domain Status:<\/strong> As an instrument authored by United States federal government employees and academic investigators funded through federal cooperative research agreements, the RBA and its companion follow-up assessments (RBFA) reside entirely in the public domain<\/strong>. No royalties, licensing agreements, or authorization fees are required to use, reproduce, adapt, or digitize the instrument for academic, non-profit, clinical, or public health research purposes.<\/p>\n Access to Full Instruments:<\/strong> Annotated codebooks, administration manuals, and the complete instrument battery can be accessed through the Substance Abuse and Mental Health Data Archive (SAMHDA)<\/a> hosted by the Inter-University Consortium for Political and Social Research (ICPSR) at the University of Michigan.<\/p>\n The following items represent authentic public-domain questionnaire items from the Risk Behavior Assessment (RBA)<\/strong>, specifically focusing on core sexual practices (Section F) and substance use immediately before or during sexual intercourse. As an interviewer-administered tool, questions are read aloud verbatim by trained field staff.<\/p>\n Interviewer Script:<\/strong> “Now, we are going to talk about your sexual practices, including each of the times you have had vaginal, oral, and anal sex. We are also talking about all types of partners: regular partners, partners for money, drugs, or whatever.”<\/p>\n Q25.<\/strong> How many days in the last 30 days have you had sex (vaginal, oral, and\/or anal)?<\/p>\n Days: [ ]<\/p>\n DK\/Unsure = 77 | Refused = 88<\/span><\/p>\n<\/p><\/div>\n<\/p><\/div>\n Q26.<\/strong> During the last 30 days, how many different people have you had vaginal, oral, and\/or anal sex with?<\/p>\n People: [ ]<\/p>\n DK\/Unsure = 777 | Refused = 888 | Skip = 999<\/span><\/p>\n<\/p><\/div>\n<\/p><\/div>\n Q27.<\/strong> How many of your sex partners were likely to have been drug injectors or shooters?<\/p>\n Partners: [ ]<\/p>\n DK\/Unsure = 777 | Refused = 888 | Skip = 999<\/span><\/p>\n<\/p><\/div>\n<\/p><\/div>\nKeywords<\/h2>\n
Authors<\/h2>\n
\n
Purpose<\/h2>\n
\n
Psychological Construct<\/h2>\n
1. Drug Consumption and Administration Modality (Sections B & D)<\/h3>\n
2. Parenteral \/ Injection Transmission Risk (Section C)<\/h3>\n
\n
3. Sexual Transmission Risk Topology (Section F)<\/h3>\n
\n
4. Commercial Sex Trading and Survival Economies (Section G)<\/h3>\n
5. Health Status, Legal Incarceration, and Economic Vulnerability (Sections E, H, I, J)<\/h3>\n
\n
Theoretical Framework<\/h2>\n
\n
Validity<\/h2>\n
1. Criterion-Related and Biological Validity<\/h3>\n
\n
2. Diagnostic and Serological Validity<\/h3>\n
\n
3. Construct and Predictive Validity<\/h3>\n
Reliability<\/h2>\n
1. Test-Retest Reliability of Sexual Risk Items<\/h3>\n
\n
2. Test-Retest Reliability of Drug Use and Paraphernalia Sharing<\/h3>\n
3. Reliability Across Auxiliary Domains<\/h3>\n
\n
Factor Analysis<\/h2>\n
1. Structural Factor Models of Drug Administration<\/h3>\n
\n
2. Factor Structure of Sexual Risk Topology<\/h3>\n
\n
Instrument \/ Measurement Tool<\/h2>\n
\n
\n
\n
7<\/code>, 77<\/code>, or 777<\/code>; Refused = 8<\/code>, 88<\/code>, or 888<\/code>; Logical Skip \/ Not Applicable = 9<\/code>, 99<\/code>, 999<\/code>, or 666<\/code>.<\/li>\n<\/ul>\n<\/li>\nPermissions, Fee, and Test Year<\/h2>\n
References<\/h2>\n
\n
Items of the Scale<\/h2>\n